Fidelity Investments’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $224K | Sell |
5,563
-26,600
| -83% | -$573K | ﹤0.01% | 3450 |
|
|
2025
Q4 | $808K | Buy |
32,163
+13,660
| +74% | +$320K | ﹤0.01% | 2933 |
|
|
2025
Q3 | $419K | Sell |
18,503
-789
| -4% | -$18.4K | ﹤0.01% | 3095 |
|
|
2025
Q2 | $334K | Sell |
19,292
-1,483,917
| -99% | -$27.5M | ﹤0.01% | 3119 |
|
|
2025
Q1 | $32.9M | Sell |
1,503,209
-624,456
| -29% | -$17.3M | ﹤0.01% | 1521 |
|
|
2024
Q4 | $67.9M | Sell |
2,127,665
-772,589
| -27% | -$23.2M | ﹤0.01% | 1273 |
|
|
2024
Q3 | $83.6M | Sell |
2,900,254
-399,536
| -12% | -$14.8M | 0.01% | 1176 |
|
|
2024
Q2 | $127M | Buy |
3,299,790
+1,121,048
| +51% | +$50.8M | 0.01% | 962 |
|
|
2024
Q1 | $128M | Buy |
2,178,742
+86,278
| +4% | +$5.5M | 0.01% | 958 |
|
|
2023
Q4 | $125M | Sell |
2,092,464
-167,302
| -7% | -$8.49M | 0.01% | 929 |
|
|
2023
Q3 | $86M | Sell |
2,259,766
-1,965,829
| -47% | -$86.4M | 0.01% | 1043 |
|
|
2023
Q2 | $385M | Buy |
4,225,595
+2,100,158
| +99% | +$181M | 0.03% | 492 |
|
|
2023
Q1 | $140M | Buy |
2,125,437
+665,274
| +46% | +$38.4M | 0.01% | 864 |
|
|
2022
Q4 | $75.5M | Sell |
1,460,163
-1
| -0% | -$53 | 0.01% | 1079 |
|
|
2022
Q3 | $99.7M | Buy |
1,460,164
+71,737
| +5% | +$4.25M | 0.01% | 959 |
|
|
2022
Q2 | $62.8M | Sell |
1,388,427
-9,165
| -0.7% | -$418K | 0.01% | 1163 |
|
|
2022
Q1 | $71M | Sell |
1,397,592
-217,267
| -13% | -$9.59M | 0.01% | 1244 |
|
|
2021
Q4 | $76.4M | Hold |
1,614,859
| – | – | 0.01% | 1235 |
|
|
2021
Q3 | $53.2M | Buy |
1,614,859
+143,694
| +10% | +$8.07M | ﹤0.01% | 1381 |
|
|
2021
Q2 | $93M | Sell |
1,471,165
-150,087
| -9% | -$7.74M | 0.01% | 1149 |
|
|
2021
Q1 | $69.6M | Buy |
1,621,252
+481,526
| +42% | +$22.8M | 0.01% | 1236 |
|
|
2020
Q4 | $65.2M | Buy |
1,139,726
+871,592
| +325% | +$36.9M | 0.01% | 1218 |
|
|
2020
Q3 | $8.09M | Sell |
268,134
-230,088
| -46% | -$6.87M | ﹤0.01% | 1894 |
|
|
2020
Q2 | $16.3M | Sell |
498,222
-20,312
| -4% | -$652K | ﹤0.01% | 1629 |
|
|
2020
Q1 | $13.9M | Sell |
518,534
-20,900
| -4% | -$742K | ﹤0.01% | 1565 |
|
|
2019
Q4 | $16.5M | Buy |
539,434
+166,300
| +45% | +$4.6M | ﹤0.01% | 1668 |
|
|
2019
Q3 | $8.99M | Buy |
373,134
+10,000
| +3% | +$275K | ﹤0.01% | 1873 |
|
|
2019
Q2 | $9.2M | Sell |
363,134
-294
| -0.1% | -$5.98K | ﹤0.01% | 1912 |
|
|
2019
Q1 | $7.09M | Sell |
363,428
-106,400
| -23% | -$1.67M | ﹤0.01% | 1977 |
|
|
2018
Q4 | $6.2M | Sell |
469,828
-97,500
| -17% | -$1.5M | ﹤0.01% | 1962 |
|
|
2018
Q3 | $10.1M | Sell |
567,328
-775,812
| -58% | -$14.3M | ﹤0.01% | 1931 |
|
|
2018
Q2 | $29.5M | Buy |
1,343,140
+345,376
| +35% | +$7.94M | ﹤0.01% | 1529 |
|
|
2018
Q1 | $22.1M | Buy |
997,764
+693,847
| +228% | +$13.6M | ﹤0.01% | 1681 |
|
|
2017
Q4 | $6.59M | Buy |
+303,917
| New | +$4.47M | ﹤0.01% | 2086 |
|
Other funds holding APLS
ACA
PCM
DTC
Fidelity Investments's APLS Position: Q1 2026 in Review
Fidelity Investments reduced its Apellis Pharmaceuticals (APLS) stake by 83% in Q1 2026, selling an estimated $573K and leaving 5,563 shares worth $224K. The position accounts for ﹤0.01% of the portfolio, ranked #3450.
Fidelity Investments first reported a position in APLS in Q4 2017 and has held it in 34 quarters since. The position peaked at $385M in Q2 2023. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.
- Fidelity Investments held 5,563 shares of Apellis Pharmaceuticals worth $224K as of Q1 2026.
- Fidelity Investments sold 26,600 Apellis Pharmaceuticals shares in Q1 2026, an estimated $573K.
- Apellis Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #3450 holding.
- Fidelity Investments first reported a position in Apellis Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- Fidelity Investments's Apellis Pharmaceuticals position peaked at $385M in Q2 2023.
- 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.
Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.